Hormone replacement therapy around and after the menopause: when and how?

1987 ◽  
Vol 25 (9) ◽  
pp. 33-36
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Ovarian Function ◽  
Hormone Replacement ◽  
Ovarian Hormones ◽  
Menopausal Symptoms ◽  
Hot Flushes ◽  
Endogenous Hormones ◽  
Exogenous Oestrogen

Women may experience various symptoms around the menopause (the perimenopause or climacteric) and later, or after hysterectomy particularly if the ovaries have also been removed. The gradual cessation of ovarian function is accompanied by a rise in gonadotrophic and a fall in ovarian hormones. The commonest symptom, hot flushes, occurs in about 75% of such women.1 Most symptoms are mild and relatively short-lived but some are severe and incapacitating. Hormone replacement therapy (HRT) aims to replace the deficiency in endogenous hormones with exogenous oestrogen. This article looks at its role in preventing or alleviating menopausal symptoms.

scholarly journals Hormone Replacement Therapy: Lebanese Women’s Awareness, Perception, and Acceptance

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
A. Anastasia Salame ◽  
Mohammad J. Jaffal ◽  
Fatin Khalifeh ◽  
Dalia Khalife ◽  
Ghina Ghazeeri
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Positive Attitude ◽  
Medical Center ◽  
Hormone Replacement ◽  
Menopausal Symptoms ◽  
World Health ◽  
Knowledge And Attitudes ◽  
The World ◽  
Whi Study

Objectives. Hormone replacement therapy (HRT) had been the gold standard for the treatment of menopausal symptoms until the publication of the World Health Initiative (WHI) study. After the WHI study, the use of HRT changed among the physicians and patients all over the world despite newer more reassuring data. This study aimed to investigate the knowledge and attitudes of women towards HRT and the factors affecting it for better counseling. Study design. A clinic-based cross-sectional study using a survey was offered to women aged 40 years and above coming to the women’s health center at the American University of Beirut Medical Center (AUBMC) from October 1st, 2017, till March 31st, 2018. The questionnaire included questions about demographics and menopausal symptoms in addition to knowledge and attitudes towards menopause and HRT. Main outcome measures. Our main hypothesis was that women would be aware of HRT as a treatment modality; however, the majority would have a negative attitude towards its usage. Results. The response rate was 87.8%. Seventy-three percent of the respondents had already heard about HRT with 57.9% supporting the use of HRT; however, 47.9% did not know when to use it. The significant predictor for having heard about HRT and a positive attitude towards HRT were having HRT prescribed as a part of treatment and employment status, respectively. Conclusions. Lebanese women are aware of HRT as a treatment option; however, a lack of both proper information and positive attitude towards HRT use was noted.

scholarly journals Hormone Replacement Therapy and Breast Diseases: A Matter of Concern for the Gynecologist

2019 ◽  
pp. 113-119 ◽  
Author(s):  
Amirhossein Eskandari ◽  
Sadaf Alipour
Keyword(s):  
Breast Cancer ◽  
Hormone Replacement Therapy ◽  
High Risk ◽  
General Population ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Menopausal Symptoms ◽  
Breast Diseases ◽  
Extensive Literature ◽  
High Risk Women

Background: The carcinogenic effect of exogenous steroid hormones on the breasts is a matter of debate, causing confusion for physicians at the time of making prescriptions. This article, as part of a quadruple series about exogenous sex hormones and breast disorders, reviews the association of breast cancer and hormone replacement therapy (HRT) in the general population, women with benign breast disorders, women with personal or family history of breast cancer, and BRCA carriers. Methods: We accomplished an extensive search of the literature by using relevant keywords to identify pertinent cohort studies, clinical trials, and reviews. Then, we extracted all points regarding the question. Results: An extensive literature exists on the risk of breast cancer following HRT in the general population, and HRT has been mentioned as a risk factor for breast cancer, especially in recent, long-term users of combined formulations. However, there is still no consensus about it. Conversely, few studies have considered challenging issues like the use of HRT in breast cancer survivors and high-risk women. Conclusion: HRT up to 5 years can safely be used for management of menopausal symptoms in healthy women, and those with low-risk benign breast disorders. On the contrary, its use in high-risk women should be limited to refractory menopausal symptoms after describing potential harms to the patient.

Management of the menopause in women with migraine

2000 ◽  
Vol 6 (2) ◽  
pp. 75-76
Author(s):  
E Anne MacGregor
Keyword(s):  
Hormone Replacement Therapy ◽  
Effective Treatment ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Prevalence Ratio ◽  
Menopausal Symptoms

Migraine is more common in women than in men, with a prevalence ratio of 3:1 respectively during the early 40s. The years leading up to the menopause mark a time of exacerbation of migraine for many women.1 Menstruation becomes a more prominent trigger and attacks often increase in frequency, as periods become increasingly irregular. Unpredictable attacks, coupled with menopausal symptoms, can make it hard for many women to cope. Unfortunately, women are often told that hormone replacement therapy (HRT) will make migraine worse and they do not receive effective treatment.

Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women

2007 ◽  
Vol 13 (3) ◽  
pp. 124-131 ◽  
Author(s):  
L A Mattsson ◽  
S Skouby ◽  
M Rees ◽  
J Heikkinen ◽  
M Kudela ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Dose Regimen ◽  
Hormone Replacement ◽  
Secondary Outcome ◽  
Estradiol Valerate ◽  
Hot Flushes ◽  
Double Blind ◽  
Early Postmenopausal Women

Objective. Continuous combined hormone replacement therapy (ccHRT) based on estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) is effective for relief of menopausal symptoms three years or more after the menopause. This study was undertaken to examine the efficacy and tolerability of ccHRT in early postmenopausal women (last menstrual period 1.3 years before study entry). Study design. This was a 52-week, randomized, double-blind, multinational study of ccHRT comprising three different dose combinations of E2V/MPA in 459 early postmenopausal non-hysterectomized women experiencing 30 or more moderate to severe hot flushes a week and/or vasomotor symptoms requiring treatment. Main outcomes measures. The primary endpoint was change in frequency and severity of moderate to severe hot flushes at 12 weeks. Secondary outcome measures included number of bleeding days and evaluation of tolerability. Results. The frequency of hot flushes was reduced by ≥70% after one month ( P<0.001 for all doses at week 2 onwards), with little evidence of statistically different dose effects. Severity of flushing was also attenuated by ccHRT. Mean number of bleeding days fell to <1 per 28-day cycle at 52 weeks. Rates of amenorrhoea approached 80–90% at the end of the study, but were significantly lower at several time points with the highest-dose regimen (2 mg E2V + 5 mg MPA) than with the lower-dose options (1 mg E2V + 2.5 mg MPA and 1 mg E2V + 5 mg MPA; P<0.05). Adverse events declined in frequency over time with all regimens but throughout the study were more numerous with the highest-dose regimen than with lower doses ( P= 0.0002). Conclusions. Continuous combined HRT was effective for the relief of climacteric symptoms in early postmenopausal women and was well tolerated.

Sign in / Sign up

Export Citation Format

Share Document